One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD

BACKGROUND: Arformoterol tartrate (arformoterol, 15 μg bid) is a nebulized long-acting β(2)-agonist approved for maintenance treatment of COPD. METHODS: This was a multicenter, double-blind, randomized, placebo-controlled study. Patients (aged ≥ 40 years with baseline FEV(1) ≤ 65% predicted, FEV(1)...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Chest
Prif Awduron: Donohue, James F., Hanania, Nicola A., Make, Barry, Miles, Matthew C., Mahler, Donald A., Curry, Lisa, Tosiello, Robert, Wheeler, Alistair, Tashkin, Donald P.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American College of Chest Physicians 2014
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4251615/
https://ncbi.nlm.nih.gov/pubmed/25451347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1378/chest.14-0117
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg